Herpes Zoster
Conditions
Interventions
None listed
Sponsors
Sendai Pain Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligible participants were patients aged 20 years or older who presented to the Sendai Pain Clinic for an initial consultation with acute to subacute zoster-associated pain (ZAP) involving the thoracic region (Th2 to Th12) within three months of rash onset, and who provided informed consent to undergo pulsed radiofrequency (PRF) treatment.
Exclusion criteria
Exclusion criteria: (1) patients with severe psychiatric disorders, including cognitive impairment (2) patients with unidentified chronic pain conditions unrelated to herpes zoster (3) patients with severe cardiovascular, respiratory, renal, or hepatic diseases (4) patients with poorly controlled diabetes mellitus (defined as HbA1c > 8.0%) (5) patients with known allergies to local anesthetics or corticosteroids (6) patients who had received neurolytic blocks related to herpes zoster within the past month (7) patients with severe dermatological conditions or active infections at the QST measurement sites.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of Quantitative Sensory Testing (QST) items measured at the initial visit between the effective and ineffective groups of PRF therapy. Items and Measurements: PPT Ratio (Affected side/Unaffected side): Pressure Pain Threshold ratio. VDT Ratio (Affected side/Unaffected side): Vibration Detection Threshold ratio. TS (WUR): Temporal Summation, recorded as Wind-up Ratio. DMA: Dynamic Mechanical Allodynia (presence/absence, VAS score). Measurement Timings of QST: At the initial visit. Three months after the onset of symptoms. Comparison: A pre- and post-treatment comparison of the QST items listed above will be performed between the two groups. Efficacy Determination: Effective Group: Maximum VAS score less than 40 mm at three months after the onset of symptoms. Ineffective Group: Maximum VAS score of 40 mm or more at three months after the onset of symptoms. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes included changes in QST parameters between the initial visit and three months after rash onset, specifically: PPT ratio, VDT ratio, temporal summation (TS, recorded as wind-up ratio [WUR]), and the presence and severity of dynamic mechanical allodynia (DMA). Additional measures included changes in maximum and average visual analog scale (VAS) scores over the same period, as well as changes in scores on the following multidimensional questionnaires: neuropathic pain screening questionnaire Hospital Anxiety and Depression Scale (HADS) Pain Catastrophizing Scale (PCS) EQ-5D-5L (a measure of health-related quality of life) | — |
Countries
Japan
Contacts
Public ContactYoshiki Kohashi
Niigata University Niigata University Graduate School of Medical and Dental Sciences, Division of Anesthesiology
Outcome results
None listed